Mark D. Kochenderfer

2.2k total citations
14 papers, 366 citations indexed

About

Mark D. Kochenderfer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mark D. Kochenderfer has authored 14 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Mark D. Kochenderfer's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Renal cell carcinoma treatment (5 papers). Mark D. Kochenderfer is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Renal cell carcinoma treatment (5 papers). Mark D. Kochenderfer collaborates with scholars based in United States, Canada and Spain. Mark D. Kochenderfer's co-authors include Diana F. Hausman, Minsig Choi, Alexander I. Spira, Antonio Jimeno, Luke Walker, Rachel Cohen, Eric Winquist, Janessa Laskin, Allen Lee Cohn and Keisuke Shirai and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal for ImmunoTherapy of Cancer.

In The Last Decade

Mark D. Kochenderfer

13 papers receiving 364 citations

Peers

Countries citing papers authored by Mark D. Kochenderfer

Since Specialization

Citations

This map shows the geographic impact of Mark D. Kochenderfer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Kochenderfer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Kochenderfer more than expected).

Fields of papers citing papers by Mark D. Kochenderfer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark D. Kochenderfer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Kochenderfer. The network helps show where Mark D. Kochenderfer may publish in the future.

Co-authorship network of co-authors of Mark D. Kochenderfer

This figure shows the co-authorship network connecting the top 25 collaborators of Mark D. Kochenderfer. A scholar is included among the top collaborators of Mark D. Kochenderfer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark D. Kochenderfer. Mark D. Kochenderfer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors. 2025 ·Journal of Clinical Oncology ·Vincent Chung, Mark D. Kochenderfer, (unknown), Grant R. Williams, (unknown), Paul Cockrum, (unknown), Andy Surinach, Li Zhang, Jia Li, Fiona Maxwell, Eileen M. O’Reilly, Zev A. Wainberg, Alice Zervoudakis	1
2	Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial 2024 ·Journal for ImmunoTherapy of Cancer ·Heinz‐Josef Lenz, Aparna R. Parikh, David R. Spigel, Allen Lee Cohn, Takayuki Yoshino, Mark D. Kochenderfer, Élena Elez, Spencer H. Shao, Dustin A. Deming, (unknown), Timothy Larson, Eric X. Chen, Amit Mahipal, (unknown), Dana Cullen, Edwina Baskin-Bey, (unknown), (unknown), (unknown), Josep Tabernero	33
3	A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort. 2022 ·Journal of Clinical Oncology ·Thomas A. Abrams, Syed Mohammad Ali Kazmi, Ira Winer, Vivek Subbiah, Gerald S. Falchook, Matthew J. Reilley, Paul R. Kunk, Sanjay Goel, Ignacio Garrido‐Laguna, Mark D. Kochenderfer, Scott Werneke, (unknown), Ramu Sudhagoni, (unknown)	14
4	Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8. 2022 ·Journal of Clinical Oncology ·Heinz‐Josef Lenz, Aparna R. Parikh, David R. Spigel, Allen Lee Cohn, Takayuki Yoshino, Mark D. Kochenderfer, Élena Elez, Spencer H. Shao, Dustin A. Deming, (unknown), Timothy Larson, Eric X. Chen, Amit Mahipal, (unknown), Dana Cullen, Edwina Baskin-Bey, Jean-Marie Ledeine, (unknown), Josep Tabernero	41
5	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma 2021 ·Journal of Clinical Oncology ·David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason, James Larkin, Rustem Gafanov, Mark D. Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexandr Poprach, Scott S. Tykodi, Teresa Alonso‐Gordoa, Daniel C. Cho, Poul Geertsen, Miguel Á. Climent Durán, Christopher DiSimone, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins	90
6	Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study 2020 ·Clinical Genitourinary Cancer ·Joshua J. McFarlane, Mark D. Kochenderfer, Mark R. Olsen, Todd M. Bauer, Ana M. Molina, Ralph J. Hauke, James A. Reeves, Sunil Babu, Peter J. Van Veldhuizen, Bradley G. Somer, Vijay Gunuganti, Ian D. Schnadig, Saby George, Ray D. Page, Edward Arrowsmith, Rohit Jain, Joshua Zhang, M. Brent McHenry, Jennifer L. Johansen, Nicholas J. Vogelzang	29
7	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427. 2020 ·Journal of Clinical Oncology ·David F. McDermott, Jae‐Lyun Lee, Frede Donskov, Scott S. Tykodi, Georg A. Bjarnason, James Larkin, Rustem Gafanov, Mark D. Kochenderfer, Jahangeer Malik, Alexandr Poprach, Sabina Signoretti, Răzvan Cristescu, (unknown), Andrey Loboda, Yiwei Zhang, Qing Zhao, Alexandra Snyder, Charles Schloss, Rodolfo F. Perini, Michael B. Atkins	12
8	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A. 2020 ·Journal of Clinical Oncology ·David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason, James Larkin, Rustem Gafanov, Mark D. Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexandr Poprach, Scott S. Tykodi, Teresa Alonso Gordoa, Daniel C. Cho, Poul Geertsen, Miguel Á. Climent Durán, Christopher Di Simone, (unknown), Rodolfo F. Perini, (unknown), Michael B. Atkins	7
9	Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study. 2019 ·Journal of Clinical Oncology ·Nicholas J. Vogelzang, Joshua J. McFarlane, Mark D. Kochenderfer, Ana M. Molina, Edward Arrowsmith, Todd M. Bauer, Ralph J. Hauke, Rohit Jain, Bradley G. Somer, Elaine T. Lam, Gurjyot K. Doshi, Vijay Gunuganti, Joshua Zhang, Huanyu Zhao, Jennifer L. Johansen, Scott S. Tykodi	13
10	Open-label phase II/III study of nivolumab plus standard of care versus standard of care for first-line treatment of metastatic colorectal cancer: Checkmate-9X8. 2019 ·Journal of Clinical Oncology ·Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Mark D. Kochenderfer, (unknown), Félix Couture, Élena Elez, Johanna C. Bendell, Ming Zhou, Dana Cullen, Heinz‐Josef Lenz	5
11	Efficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) + regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC). 2017 ·Journal of Clinical Oncology ·David R. Fogelman, Johanna C. Bendell, Antonio Cubillo, Pilar Alfonso, (unknown), John Nemunaitis, Daniel Flora, Christophe Borg, Laurent Mineur, (unknown), Allen Lee Cohn, Gene Saylors, Albert Assad, Julie Switzky, (unknown), Li Zhou, Mark D. Kochenderfer	2
12	A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma 2016 ·Clinical Colorectal Cancer ·Daniel W. Bowles, Mark D. Kochenderfer, Allen Lee Cohn, Lucas Sidéris, Nghia Nguyen, (unknown), Ian D. Schnadig, Minsig Choi, Lisle M. Nabell, Arvind Chaudhry, Robert L. Ruxer, (unknown), Diana F. Hausman, Luke Walker, Alexander I. Spira, Antonio Jimeno	37
13	Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r) metastatic colorectal cancer (mCRC). 2015 ·Journal of Clinical Oncology ·David R. Fogelman, Mark D. Kochenderfer, Gene Saylors, Fadi S. Braiteh, John Nemunaitis, Allen Lee Cohn, (unknown), Li Zhou, Julie Switzky, Albert Assad, Johanna C. Bendell	0
14	A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer 2014 ·Annals of Oncology ·Antonio Jimeno, Keisuke Shirai, Minsig Choi, Janessa Laskin, Mark D. Kochenderfer, Alexander I. Spira, (unknown), Eric Winquist, Diana F. Hausman, Luke Walker, Rachel Cohen	82

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact